MBX Biosciences updates pipeline in Q3 2026 results, cash runs into 2029
MBX highlighted its pivotal Phase 3 hypoparathyroidism trial dosing and said MBX 4291 obesity data are on track for Q4 2026, with $481.6 million in cash.
MBX Biosciences reported third-quarter 2026 results on November 9, 2026, highlighting progress across its pipeline of peptide therapies for endocrine and metabolic disorders.
The company said in August 2026, MBX announced the dosing of the first patient in its pivotal Phase 3 oPTimize trial1 of once-weekly canvuparatide for chronic hypoparathyroidism. The global trial is randomized, double-blind and placebo-controlled, and is expected to enroll approximately 160 adults with chronic hypoparathyroidism1. MBX said the trial builds on prior Phase 2 Avail results and on clinical benefit sustained through one year of treatment in an open-label extension study1.
For its obesity program, MBX said it remains on track to report unblinded data from the first cohort of the 12-week multiple ascending dose portion of its ongoing Phase 1 trial of MBX 42911 in the fourth quarter of 2026. That cohort is testing a titration regimen starting at 30 mg once weekly for four weeks, then stepping up to 120 mg and 180 mg once monthly, in adults with a BMI of 30 kg/m2 or higher1.
MBX also said IND-enabling work continues for MBX 5765, its amycretin prodrug candidate combining GLP-1, GIP, glucagon and dual amylin/calcitonin receptor agonist activity in one peptide1, and that preclinical pharmacokinetic data on MBX 6180, a once-monthly triple agonist prodrug candidate, were accepted for a poster at ObesityWeek 2026, running November 14-17 in Washington, D.C., with IND-enabling studies for that program also ongoing.
On the corporate side, MBX said in October 2026 it appointed Peter Radovich, President and Chief Operating Officer of Mirum Pharmaceuticals, to its board1, and in September 2026 named Jeff Held, J.D., as Chief Legal Officer1.
On finances, the company said it held $481.6 million in cash, cash equivalents and marketable securities as of September 30, 2026, reflecting $97.6 million in net proceeds from its at-the-market stock sales, and expects that balance to fund operations into 20291.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.